Michiel Dalinghaus is pediatric cardiologist at the Sophia Children’s Hospital/Erasmus MC, Rotterdam. He is medical director of Pediatric Heart Failure & Transplantation, which is the national referral centre for (end-stage) heart failure and transplantation in children.
His research has focussed on the clinical characterization of severe/end-stage heart failure in children. The last 10 years he led nationwide studies, which characterized risk factors for outcome in children with dilated cardiomyopathy and genetics of disease (CARS Iⅈsupported by the Stichting Hartedroom & NHF) and acted as PI for DCM in a European study on pharmacological aspects of enalapril (LENA consortium; EU-FP7 funded). In cooperation with prof Jolanda van der Velden (VuMC) a bed-to-bench study to characterize abnormalities of contractile properties of cardiac myocytes in pediatric end-stage heart failure was performed. This cooperation will continue within the Double Dose consortium, allowing to further unravel underlying mechanisms in pediatric cardiomyopathy.
Contact: m.dalinghaus@erasmus.nl